

University of Nebraska Medical Center Curriculum Vitae

Name: Christopher Jon Kratochvil, M.D.

Address:

987878 Nebraska Medical Center
Omaha, NE 68198-7878

Phone: (402) 559-8480 **Fax** (402) 559-8445

E-mail: ckratoch@unmc.edu

Education:

M.D., Doctor of Medicine, Creighton University, Omaha, NE, August 1987-May 1992

B.A., Psychology, Creighton University, Omaha, NE, August 1983-May 1987

Post-Degree Training:

Chief Resident in Child & Adolescent Psychiatry, Duke University Medical Center, Durham, NC, July 1996-June 1997

Resident in Child & Adolescent Psychiatry, Duke University Medical Center, Durham, NC, July 1995-June 1997

Associate Chief Resident in Psychiatry, Creighton-Nebraska University, Omaha, NE, July 1994-June 1995

Resident in Psychiatry, Creighton-Nebraska University, Omaha, NE, July 1992-June 1995

Academic Appointments:

Assistant Vice-Chancellor for Clinical Research, University of Nebraska Medical Center, Omaha, NE 2010-Present

Chief Medical Officer, UNeHealth, Omaha, NE February 2010-Present

Professor, Psychiatry, University of Nebraska Medical Center, Omaha, NE, July 2008-Present

Professor, Pediatrics (Courtesy), University of Nebraska Medical Center, Omaha, NE, May 2008-Present

Clinical Professor, Psychiatry, Creighton University School of Medicine, Omaha, NE, May 2009-Present

Director, Division of Child & Adolescent Psychiatry, University of Nebraska Medical Center, Omaha, NE 2008-2010

Clinical Service Chief, Child & Adolescent Psychiatry, Children's Hospital and Medical Center, 2009-2010

Faculty Associate, UNMC Center for Humanities, Ethics & Society, 2009-Present

Associate Professor, Psychiatry, University of Nebraska Medical Center, Omaha, NE, July 2003-2008

Associate Professor, Pediatrics (Courtesy), University of Nebraska Medical Center, Omaha, NE, May 2005-2008

Graduate Faculty, University of Nebraska, March 2001-Present

Interim Director, Psychopharmacology Research Consortium, University of Nebraska Medical Center, Omaha, NE, July 2006-June 2007
Assistant Director, Psychopharmacology Research Consortium, University of Nebraska Medical Center, Omaha, NE, July 2000-Present
Faculty Affiliate, Nebraska Center for Research on Children, Youth, Families and Schools, University of Nebraska, Lincoln, NE, January 2006-Present
Assistant Professor, Psychiatry, University of Nebraska Medical Center, Omaha, NE, July 1999-June 2003
Clinical Assistant Professor, Psychiatry, Creighton University, Omaha, NE, July 1999-2005
Assistant Professor, Psychiatry, Creighton University School of Medicine, Omaha, NE, July 1998-June 1999
Medical Director, Residential Treatment Center, Saint Joseph Center for Mental Health, Omaha, NE, 1998-1999
Director, Outpatient Services, Division of Child & Adolescent Psychiatry, Creighton-Nebraska Department of Psychiatry, Omaha, NE, July 1997-June 1999
Instructor, Psychiatry, Creighton University School of Medicine, Omaha, NE, July 1997-June 1998
Co-Director, Behavioral Pediatrics Clinic, Creighton University Department of Pediatrics, Omaha, NE, July 1997-June, 1998
Clinical Instructor, Psychiatry, University of Nebraska Medical Center, Omaha, NE, July 1997-June 1999

Board Certification and Licenses:

Nebraska State Board of Medical Examiners, M.D., License # (b) (6), 1993-Present
American Board of Psychiatry & Neurology, Added Qualifications in Child & Adolescent Psychiatry, 1999; recertification 2009
American Board of Psychiatry & Neurology, in Psychiatry, 1998; recertification 2008

Grant and Contract Support

National Institutes of Health Grants

Enhancing Pediatric Psychopharmacology in the Medical Home; National Institutes of Health, (1 RC1 MH088922-01) 2009-Present; PI: Peter Jenson, M.D., **Co-Investigator: Christopher Kratochvil, M.D.**
Prevention of Depression in Patients Being Treated for Head and Neck Cancer; National Institutes of Health, 2007-Present; PI: William Burke, M.D., **Co-Investigator: Christopher Kratochvil, M.D.**
Substance Use Outcomes Following Treatment for Adolescent Depression (SOFTAD); National Institute of Mental Health, Subcontract through Duke University, 2004-2009; **PI: Christopher Kratochvil, M.D.**
Pharmacological Treatment of ADHD in Young Children, a Mentored Patient-Oriented Research Career Development Award (K-23) in Response to PA-00-004. (5K23MH066127-03) 2003-2009; **PI: Christopher Kratochvil, M.D.**

Genetic Linkage Study of Children with Attention Deficit Hyperactivity Disorder; National Institute of Mental Health, Subcontract through Harvard Medical School, 2003-2006; **PI: Christopher Kratochvil, M.D.**

Treatment for Adolescents with Depression Study (TADS); National Institute of Mental Health, Subcontract through Duke University, 1999-2005; Site **PI: Christopher Kratochvil, M.D.**

A Multi-Center Study of the Validity, Reliability, and Consumer Satisfaction of the Pediatric Adverse Event Rating Scale (PAERS): A Likert-Style Adverse Event Reporting Questionnaire; National Institute of Mental Health, Subcontract through Duke University, 2005; **Site PI: Christopher Kratochvil, M.D.**

National Center for Research Resources

IRB Training Through a Web-Based Protocol Review Form; NIH S07 Award, 2003-2004; PI: Ernest Prentice, Ph.D., **Co-Investigator: Christopher Kratochvil, M.D.**

State and Local Grants

Genetic and Biochemical Markers in Children with ADHD; (b) (6). Children's Healthcare Fund, 2000- 2003; **PI: Christopher Kratochvil, M.D.**

Genetic and Biochemical Markers in Children with ADHD; UNMC College of Medicine Translational/Collaborative Grant, 2000-2003; **PI's:** David Bylund, Ph.D., Shelley Smith, Ph.D., **Christopher Kratochvil, M.D.**

Candidate Genes in Drug Responsive Children with ADHD; Ittner Foundation, 2000-2002; PI: (b) (6), M.D., **Co-Investigator: Christopher Kratochvil, M.D., et al.**

Other Grant and Contract Support

1. (b) (4)
- 2.
- 3.
- 4.
- 5.

(b) (4)

6.

7.

8.

9.

10

11

12

13

14

15

16

17

(b) (4)

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

(b) (4)

30.

31.

32.

33.

34.

35.

36.

37.

38.

(b) (4)

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

(b) (4)



49.

50.

51.

52.

53.

54.

55.

56.

57.

58.  (b) (4)

59.

60.

61.

62. Immune Function in Treatment Resistant Depression; UNMC, 2000-2002; PI: William Burke, M.D., **Co-Investigator: Christopher Kratochvil, M.D.**, et al.

63.  (b) (4)

64.

65.

66.

67.

68.

69.

70.

(b) (4)

71.

72.

73.

74.

75.

76.

77.

78.

79.

80.

81.

82.

(b) (4)

Consulting Positions:

Editorial

- Pediatric Psychopharmacology: Principles & Practice, 2nd Edition
 - Oxford Press, 2011
 - Martin, Scahill and Kratochvil editors
- Journal of the American Academy of Child & Adolescent Psychiatry
 - Editorial Board, 2009-Present
 - Assistant Editor, 2004-2009
 - Reviewer, 2002-Present
- Journal of Attention Disorders
 - Editorial Board, 2005-Present
 - Reviewer, 2006-Present
- Journal of ADHD and Related Disorders
 - Associate Editor, 2010
- Child and Adolescent Psychiatry and Mental Health
 - Editorial Board, 2006-Present
- Brown University Child and Adolescent Psychopharmacology Update
 - Editor, 2007-2010
 - Guest Editor, May 2003, Feb 2006, March 2006, May 2006-2007
- Psychiatric Annals
 - Guest Editor, April 2010
- Pediatric Drugs
 - Editorial Board, 2006-Present
- American Society of Clinical Psychopharmacology
 - Co-Editor, Child & Adolescent Section, Model Curriculum on Psychopharmacology, 2007-2010
- Neuropsychiatry
 - Editorial Advisory Board, 2010-present
- Prior Ad Hoc Reviewer
 - International Clinical Psychopharmacology, Biological Psychiatry, CNS Spectrums, Journal of Clinical Psychiatry, Pediatrics, Journal of Child & Adolescent Psychopharmacology, Bipolar Disorders - An International Journal of Psychiatry and Neurosciences, Expert Opinion on Drug Delivery, Journal of Child Psychology, Psychiatry, and Allied Disciplines, Drug Benefit Trends, Drug Safety, Expert Review of Neurotherapeutics, Doody Publishing, US Pharmacopeia, Pharmacological Reviews

National Institute of Mental Health

- Interventions Committee for Disorders Involving Children and Their Families (ITVC), National Institute of Mental Health Initial Review Group
 - 2009, 10/5/09

- 2008/10, 6/10/08-6/11/08
- 2008/05, 2/12/08
- 2008/01, 10/10/07-10/11/07
- 2007/10, 6/19/07
- 2007, 2/13/07-2/14/07
- 2007/01, 10/10/06
- 2006/10, 6/20/06
- Child Interventions Panel/Special Emphasis Panel/Initial Review Group
 - 2008/01 ZMH1 ERB-M 02 S, 10/18/07 (Chair of Panel)
 - 2007 ZMH1-ERB-D (05), 12/11/06
 - 2006/08 ZMH1 ERB-P (07), 2/8/06-2/9/06
 - 2006/01 ZMH1 ERB-P (01), 10/24/05-10/25/05
 - 2005/ ZMH1 ERB-P (07), 6/14/2005-6/15/2005
 - 2005/05 ZMH1 ERB-P (05), 2/8/2005-2/9/2005
 - 2005/01 ZMH1 ERB-P (02) (S), 10/13/2004-10/14/2004.
- NIMH Loan Repayment Program, Reviewer
 - ZMH1 IRB-I C1, April 4, 2011
 - ZMH1 ERB-I C3, March 30, 2009
 - ZMH1 ERB-Y March 27, 2007
 - ZMH1 ERB-G C3 S, March 28, 2006
 - ZMH1 ERB-M, May 16, 2005
 - ZMH1 DEA-M (C8), May 13-14, 2004
 - ZMH1, May, 2003
- Developing & Advance Centers for Intervention and Services Research
 - ZMH1 ERB-F (01) October 22, 2010
- Data Safety Monitoring Board; 5R01MH070935-04 / 3R01MH070935
Predicting Response to Atomoxetine and
Methylphenidate/Methylphenidate and Atomoxetine in ADHD, 2007-
Current
- Data Safety Monitoring Board, Chair; Pediatric MDD: Sequential
Treatment with Fluoxetine and Relapse Prevention CBT, Data Safety
Monitoring Board, 2008-Present R01-MH39188
- Data Safety Monitoring Board; 1R01HD060617-01A1, Reading ICARD:
Interventions for Children with Attention and Reading Disorders, 2010-
Present
- Management of Excessive Psychotropic Medication for Youth in Out-of-
Home Care 1 R13 MH094101-01 NIMH/NICHD 05/01/2011 – 09/30/2011
Invited Expert Participant: Christopher Kratochvil, M.D.

Netherlands Organization for Health Research and Development

- Prevention Program, grant review, 2/27/07

Catalan Agency for Health Technology Assessment and Research, Spain

- Grant reviewer, 2009

Clinical

- Samaritan Counseling Center, Omaha, NE; Psychiatric Consultant, 2000-2002
- Nebraska Department of Human Services, Lincoln, NE; Site Inspector & Psychiatric Consultant; 1997-2001
- Boys Town, Psychopharmacology Instruction for Staff Development Nationally, Boys Town, NE; 1997-1999
- Consultant - Lutheran Family Services, Bellevue, NE; Psychiatric Consultant; 1997-1998

Industry

- Data Safety Monitoring Board, Pfizer
 - 4 pediatric protocols, 2011-present
 - 4 pediatric protocols, 2005-2009
- Data Safety Monitoring Board, Seaside
 - 3 protocols, 2011-present
- Data Safety Monitoring Board, AstraZeneca
 - 2 pediatric protocols, 2004-2007
- Data Safety Monitoring Board, Organon
 - 3 pediatric protocols, March 2003-2006
- Quintiles- Consultant 2010—Present
- Theravance Advisor 2010-Present
- AstraZeneca, ADHD Advisory Board, 2009
- Abbott, National Advisory Board, 2007-2008
- National Alliance for the Advancement of ADHD Care, National Advisory Board, June 2002-2003
- Eli Lilly & Company, Global ADHD Advisory Board, 2002-2007
- Eli Lilly & Company, National ADHD Advisory Board, 2001-2005
- Boehringer Ingelheim, Consultant, 2005
- Cephalon, ADHD Executive Advisory Board, 2005-2006
- Shire Pharmaceuticals, ADHD Advisory Board, 2002, 2005

CME

- Primary Pediatric Psychopharmacology Steering Committee (PPP-SC), in collaboration with the REACH Institute (The Resource for Advancing Children's Health) 2006-Present
- CME Outfitters, Professional Advisory Board, 2006-2007
- Massachusetts General Hospital Psychiatry Academy, Affiliate Faculty, 2005-2006

Honors and Awards:

- Fellow of the American Academy of Child & Adolescent Psychiatry, 2010-Present
- Fellow of the American Psychiatric Association, 2009-Present
- Distinguished Scientist, University of Nebraska Medical Center, 2008

- Klingenstein Third Generation Foundation Award for Research in Depression or Suicide, awarded by the American Academy of Child & Adolescent Psychiatry to the Treatment for Adolescents with Depression (TADS) Team, 2007
- Visiting Professor; University of Ulm; Ulm, Germany June, 2007
- Best Doctors in America, 2005-2006, 2007-2008, 2009-2010, 2011-2012
- AACAP Outstanding Mentor Award, 2005
- Chancellor's Silver "U" Award, 2003
- Assembly William Sorum Award, American Psychiatric Association, 1995
- Outstanding Service Award, Nebraska Psychiatric Association, 1995
- Cecil Wittson Award for Outstanding Resident, Creighton-Nebraska Department of Psychiatry, 1994

Professional Organizations:

BioNebraska Life Sciences Organization: Board of Directors 2011-Present

Professional Societies:

American Academy of Child & Adolescent Psychiatry: Member 1995- Present

Member of Council (National Board of Directors)

- October, 2007-October 2010

National Committees

- Telemedicine Committee, 2002-2004
- Pediatric Psychopharmacology Initiative, 2001-Present
 - Chair, 2006-2010
 - Ethics Subcommittee, 2003-2005
- Work Group on Research, 2001- Present
 - Executive Committee, 2003-2007
- Early Investigators Group, Co-Chair annual meeting, 2004

American Psychiatric Association: Member 1993- Present

National Committees

- Council on Children, Adolescents and Their Families, Member, 2009-2011
 - Vice-Chair, 2009-2011
- Council on Research, Consultant 2007-2009
- Council on Children, Adolescents and Their Families, Consultant 2008-2009
- Joint Commission on Public Affairs, 1994-1995

Regional Committees

- Area IV Council, 1994-1995

American Society of Clinical Psychopharmacology: Member 2007-Present

American Medical Association: Member 2000-Present

Nebraska Council of Child & Adolescent Psychiatry: Member 1997-Present

Offices

- President, 2005-2007

- President, 2000-2002
- Secretary/Treasurer, 1998-2000

Nebraska Psychiatric Society: Member 1997-Present

Offices

- Executive Committee, Early Career Psychiatrist Representative, 1997-2000
- Program Committee, 1997-1999
- Executive Committee, Member in Training Representative, 1994-1995

Nebraska Medical Association: Member 1999-Present

Offices

- Commission on Legislative and Government Affairs, 2001-2003

Metro Omaha Medical Society: Member 1999-2009

North Carolina Council of Child & Adolescent Psychiatry: Member 1995-1997

Offices

- Executive Council, 1996-1997

Committee Assignments:

University of Nebraska Medical Center/Children's Hospital

- Joint Pediatric Institutional Review Board
 - Consultant, 2010-Present
 - Vice Chair, 2009-2010

University of Nebraska Medical Center Committees:

- Institutional Review Board #2
 - Consultant 2010-Present
 - Vice Chair, 2002-2010
 - Member, 2002-2010
- Institutional Review Board #1
 - Consultant 2010-Present
 - Vice Chair, 2002-2010
 - Member, 2002-2010
- Research Enterprise Committee, Member, 2003-2006
- Clinical Investigation Advisory Board, Member, 2002-2006
- Ittner and Seed Grant Reviewer, 2002-2003
- Developmental Neuroscience Research Group, Member, 1999-2000

UNMC Department of Psychiatry

- Promotion & Tenure Committee, 2010-Present

State of Nebraska

- Nebraska State Behavioral Health Emergency Response Team (B-HERT); 2009-2010
- Children's Mental Health and Substance Abuse State Infrastructure Grant
 - Steering Committee, 2005-2009
 - Academic Committee, 2005-2009

- Behavioral Health Reform Project, Academic Support Subgroup, 2004-2005
- Center of Excellence White Paper Committee for Governor Johanns, 2003

Nebraska Area Health Education Centers

- Fund Advisory Committee, 2007-2008

Creighton University

- Faculty Council, Member, 1998-1999
- Academic Council, Member, 1998-1999
- Compliance Committee, 1998

University of Nebraska Department of Psychiatry

- Psychiatry Symposium Committee, Member, 2001-2006
- Department of Psychiatry Research Development Committee, Member, 2001-2004
- Space Committee, Member, 1999-2001

Creighton-Nebraska Psychiatry Residency Training Program

- Child & Adolescent Residency Training Committee, Member, 1997-2000, 2006-2010
- Child & Adolescent Residency Curriculum Development Committee, 1998-1999

Community Service

- Building Bright Futures School-Based Health Center Advisory Board, 2010-Present
- [REDACTED] (b) (6)
- [REDACTED]
- Medical Reserve Corp, 2005-2006
- [REDACTED] (b) (6)
- [REDACTED]
- Children & Adults with Attention Deficit Hyperactivity Disorder (CHADD), Omaha, NE; Professional Advisory Board; 1999-2006

Articles Published in Scholarly Journals

1. Correll CU, **Kratochvil CJ**, March JS (2011). Developments in Pediatric Psychopharmacology: Focus on Stimulants, Antidepressants, and Antipsychotics. *J Clin Psychiatry*. 72(5):655-670.
2. Apostol G, Abi-Saab W, **Kratochvil CJ**, Adler LA, Robieson WZ, Gault LM, Pritchett YL, Feifel D, Collins MA, Saltarelli MD (2011). Efficacy and safety of the novel $\alpha(4)\beta(2)$ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. *Psychopharm* July 12, epub ahead of print.
3. **Kratochvil CJ**, Vaughan, B, Stoner J, Daughton, JM, Lubberstedt B, Murray D, Chrisman A, Faircloth J, Itchon-Ramos N, Kollins S, Maayan L, Greenhill L, Kotler L, Fried J March J (2011). A Double-Blind, Placebo-

- Controlled Study of Atomoxetine in Young Children with ADHD. *Pediatrics*. 127(4)
4. Vaughan BS, March JS, **Kratochvil CJ** (2011). The Evidence-Based Pharmacological Treatment of Pediatric ADHD. *Int J Neuropsychopharmacol*. 18:1-13 epub ahead of print.
 5. Wilens TE, Gault LM, Childress A, **Kratochvil CJ**, Bensman L, Hall CM, Olson E, Roieson WZ, Garimella TS, Abi-Saab WM, Apostol G, Saltarelli MD (2011). Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials. *J Am Acad Child Adolesc Psychiatry*. 50(1):73-84.
 6. May DE, **Kratochvil CJ** (2010). Attention-Deficit/Hyperactivity Disorder: Recent Advances in Pediatric Pharmacotherapy. *Drugs* 70(1):15-40.
 7. Yu ZJ, **Kratochvil CJ**, Weller RA, Mooreville M, Weller EB (2010). From TADS and SOFTADS to TORDIA and Beyond: What's New in the Treatment of Adolescent Depression. *Curr Psychiatry Rep*. 12:88-95.
 8. Daughton J, Liu H, West M, Swanson D, **Kratochvil CJ** (2010). Practical Guide to ADHD Pharmacotherapy. *Psychiatric Annals* 40(4):210-217.
 9. **Kratochvil CJ**, May DE, Silva SG, Madaan V, Puumala SE, Curry JF, Walkup J, Kepley H, Vitiello B, March JS (2009). Treatment Response in Depressed Adolescents with and without Co-Morbid Attention-Deficit/Hyperactivity Disorder in the Treatment for Adolescents with Depression Study. *J Child Adolesc Psychopharm*. 19(5):519-528.
 10. Newcorn JH, Sutton VK, Zhang S, Wilens T, **Kratochvil C**, Emslie GJ, D'Souza DN, Schuh LM, Allen AJ (2009). Characteristics of Placebo Responders in Pediatric Clinical Trials of Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry*. 48(12):1165-1172.
 11. Treatment for Adolescents with Depression Study (TADS) Team (2009). The Treatment for Adolescents with Depression Study (TADS): Outcomes Over 1 year of Naturalistic Follow-Up. *Am J Psychiatry*. 116(10):1141-1149.
 12. Daughton JM, **Kratochvil CJ** (2009). Review of ADHD Pharmacotherapies: Advantages, Disadvantages, and Clinical Pearls. *J Am Acad Child Adolesc Psychiatry*. 48(3):240-248.
 13. **Kratochvil CJ**, Vaughan BS, Barker A, Corr L, Wheeler A, Madaan V (2009). Review of Pediatric Attention Deficit/Hyperactivity Disorder for the General Psychiatrist. *Psychiatr Clin North Am*. 32(1):104-117.
 14. Schonfeld TL, Amoura NJ, **Kratochvil CJ** (2009). iPLEDGE Allegiance to the Pill: Evaluation of Year 1 of a Birth Defect Prevention and Monitoring System. *J Law Med Ethics*. 37(1):104-117.
 15. Domino ME, Foster EM, Vitiello B, **Kratochvil CJ**, Burns BJ, Silva SG, Reinecke MA, March JS. (2009) The Relative Cost-Effectiveness of Treatment for Adolescent Depression: 36-week Results from the TADS Randomized Trial. *J Am Acad Child Adolesc Psychiatry*. 48(7):711-720.

16. Vaughan BS, Fegert JM, **Kratochvil CJ** (2009). Update on Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder. *Expert Opin Pharmacother.* 10(4):669-676.
17. Vitiello B, Silva S, Rohde P, **Kratochvil C**, Kennard B, Reinecke M, Mayes T, Posner K, May DE, March JS (2009). Suicidal Events in the Treatment for Adolescents with Depression Study (TADS). *J Clin Psychiatry* 70:741-747.
18. Kennard BD, Silva SG, Mayes T, Rohde P, Hughes JL, Vitiello B, **Kratochvil CJ**, Curry JF, Emslie GJ, Reinecke MA, March JS (2009). Long term outcomes of acute phase treatment with placebo in the Treatment for Adolescents with Depression Study (TADS). *Am J Psychiatry.* 166(3):337-344.
19. Rogers GM, Park JH, Essex MJ, Klein MH, Silva SG, Hoyle RH, Curry JF, Feeny NC, Kennard B, **Kratochvil CJ**, Pathak S, Reinecke MA, Rosenberg DR, Weller EB, March JS (2009). The dysfunctional attitudes scale: psychometric properties in depressed adolescents. *J Clin Child Adolesc Psychology* 38(6):781-789.
20. Domino ME, Burns BJ, Mario J, Reinecke MA, Vitiello B, Weller EB, **Kratochvil CJ**, May D, Feeny N, Robins M, Hallin M, Silva SG, March JS. (2009). Service use and costs of care for depressed adolescents: Who uses and who pays? *J Clin Child Adolesc Psychology* 38(6):826-836.
21. Jacobs RH, Silva SG, Reinecke MA, Curry JF, Ginsburg GS, **Kratochvil CJ**, March JS (2009). DAS Perfectionism: A predictor of acute treatment outcome among clinically depressed adolescents. *J Clin Child Adolesc Psychology* 38(6):803-813.
22. Kennard BD, Silva SG, Tonev S, Rohde P, Hughes JL, Vitiello B, **Kratochvil CJ**, Curry JF, Emslie GJ, Reinecke M, March JS (2009). Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): Acute and long-term outcomes. *J Am Acad Child Adolesc Psychiatry.*
23. Jacobs R, Klein J, Reinecke M, Silva SG, Tonev S, Breland-Noble A, Martinovich Z, **Kratochvil CJ**, Rezak AJ, Jones J, March JS (2008). Ethnic differences in attributions and treatment expectancies for adolescent depression. *Int J Cog Therapy* 1: 163-178.
24. Zito J, Derivan A, **Kratochvil C**, Safer D, Fegert J, Greenhill L (2008). Off-label Psychopharmacologic Prescribing for Children: History Supports Close Clinical Monitoring. *Child Adolesc Psychiatry Ment Health*, 2:24.
25. **Kratochvil C**, Milton D, Vaughan B, Greenhill L (2008). Acute Atomoxetine Treatment of Younger and Older Children With ADHD: A Meta-Analysis of Tolerability and Efficacy. *Child Adolesc Psychiatry Ment Health*, 2:25.
26. Domino ME, Burns BJ, Silva SG, **Kratochvil CJ**, Vitiello B, Reinecke MA, Mario J, March J (2008). The Cost-Effectiveness of Treatments for Adolescent Depression: Results from the Treatment for Adolescents with Depression Study (TADS). *Am J Psychiatry.* 165:588-596.

27. Feeney NC, Silva SG, Reinecke MA, McNulty S, Findling RL, Rohde P, Curry JF, Ginsburg GS, **Kratochvil CJ**, Pathak S, May D, Kennard E, Simons AD, Wells K, Robins M, Rosenberg D, March JS (In Press). An Exploratory Analysis of Impact on Family Functioning on Treatment for Depression in Adolescents. J Clin Child Adolesc Psychology.
28. Rohde P, Silva SG, Tonev ST, Kennard BD, Vitiello B, **Kratochvil CJ**, Reinecke MA, Curry JF, Simons AD, March JS (2008). Achievement and Maintenance of Sustained Response During the Treatment for Adolescents with Depression Study (TADS) Continuation and Maintenance Therapy. Arch Psychiatry. 65:447-455.
29. Vaughan BS, Wetzel MW, **Kratochvil CJ** (2008). Beyond the 'Typical' Patient: Treating Attention-Deficit/Hyperactivity Disorder in Preschoolers and Adults. Int Rev Psychiatry. 20(1).
30. Greenhill LL, Posner K, Vaughan BS, **Kratochvil CJ** (2008). Attention deficit hyperactivity disorder in preschool children. Child Adolesc Psychiatric Clin N Am. 17(2):347-366.
31. Newcorn JH, **Kratochvil CJ**, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D, Atomoxetine/Methylphenidate Comparative Study Group (2008). Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response. Am J Psychiatry.
32. Dell ML, Vaughan BS, **Kratochvil CJ** (2008). Ethics and the Prescription Pad. Child Adolesc Psychiatric Clin N Am. 17:93-111.
33. Bhatia SK, Rezac AJ, Vitiello B, Sitorius MA, Buehler BA, **Kratochvil CJ** (2008). Antidepressant Prescribing Practices for the Treatment of Children and Adolescents. J Child Adolesc Psychopharmacology. 18(1):70-80.
34. Compton SN, **Kratochvil CJ**, March JS (2007). Pharmacotherapy for Anxiety Disorders in Children and Adolescents: An Evidence-Based Medicine Review. Psychiatric Annals. 37(7):504-517.
35. Madaan V, Daughton J, Lubberstedt B, Mattai A, Vaughan BS, **Kratochvil CJ** (2008) Assessing the Efficacy of Treatments for ADHD: Overview of Methodological Issues. CNS Drugs. 22(4):275-290.
36. Vitiello B, **Kratochvil CJ**, Silva S, Curry J, Reinecke M, Pathak S, Waslick B, Hughes C, Prentice ED, May DE, March JS (2007). Research Knowledge Among the Participants in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 46(12):1642-1650
37. DelBello MP, Correll CU, Carlson GA, Carlson HE, **Kratochvil CJ** (2007). Pharmacological Management of Bipolar Disorder in a Youth with Diabetes J Am Acad Child Adolesc Psychiatry. 46(10):1375-1379
38. Emslie GJ, Waslick B, Weller EB, Kloos A, Weller RA, **Kratochvil CJ** (2007). Antidepressant Management in the Context of Suicidal Ideation. J Am Acad Child Adolesc Psychiatry. 46(9):1222-1225
39. Spencer TJ, **Kratochvil CJ**, Sangal RB, Saylor KE, Bailey CE, Dunn DW, Casat CD, Lipetz RS, Jain R, Newcorn JH, Ruff DD, Feldman PD, Furr AJ,

- Allen AJ (2007). Effects of Atomoxetine on Growth in Children with ADHD Following up to Five Years of Treatment. J Child Adolesc Psychopharmacology, 17(5):689-700
40. **Kratochvil CJ**, Michelson D, Newcorn JH, Weiss MD, Busner J, Moore RJ, Ruff DD, Ramsey J, Dickson R, Turgay A, Saylor KE, Lubner S, Vaughan B, Allen AJ, and the Atomoxetine High-dose Study Group (2007). High-dose Atomoxetine Treatment of ADHD in Youths with Limited Response to Standard Doses. J Am Acad Child Adolesc Psychiatry, 46(9):1128-1137
41. Perwien AR, **Kratochvil CJ**, Faries D, Vaughan B, Busner J, Saylor KE, Buermeyer CM, Kaplan S, Swindle R (2008). Emotional Expression in Children Treated with ADHD Medication: Development of a New Measure. J of Attention Disorders 11(5):568-579.
42. May DM, Hallin MJ, **Kratochvil CJ**, Puumala SE, Reinecke MA, Silva SG, Weller EB, Vitiello B, Breland-Nobel A, March JS (2007). Factors Associated with Recruitment and Screening in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 46(7):801-810
43. **Kratochvil CJ**, Vaughan BS, Mayfield-Jorgensen ML, March JS, Kollins SH, Murray DW, Ravi H, Greenhill LL, Kotler LA, Paykina N, Biggins P, Stoner J. (2007). A Pilot Study of Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 17(2):175-185
44. March JS, Szatmari P, Bukstein O, Chrisman A, Kondo D, Hamilton J, Kremer CME, **Kratochvil CJ** (2007). AACAP 2005 Research Forum: speeding the Adoption of Evidence-Based Practice in Pediatric Psychiatry. J Am Acad Child Adolesc Psychiatry, 46(9):1098-1110
45. Findling RL, Newcorn JH, Malone RP, Waheed A, Prince JB, **Kratochvil CJ** (2007). Pharmacotherapy of Aggression in a 9-year-old with ADHD. J Am Acad Child Adolesc Psychiatry 46(5):653-658
46. Treatment for Adolescents with Depression Study Team (TADS) (2007). The Treatment for Adolescents with Depression Study (TADS): Long-Term Effectiveness and Safety Outcomes. Arch Gen Psychiatry 64(10):1132-1143
47. May DE, **Kratochvil CJ**, Puumala SE, Silva SG, Rezac AJ, Hallin MJ, Reinecke MA, Vitiello B, Pathak S, Simons AD, Weller EB, March JS (2007). A Manual-Based Intervention to Address Clinical Crises and Retain Patients in the Treatment of Depression for Adolescents Study (TADS) J Am Acad Child Adolesc Psychiatry 46(5):573-581
48. **Kratochvil CJ**, Faries D, Vaughan B, Perwien A, Busner J, Saylor K, Kaplan S, Buermeyer C, Swindle R (2007). Emotional Expression During Attention-Deficit/Hyperactivity Disorders Treatment: Initial Assessment of Treatment Effects. J Child Adolesc Psychopharmacol 17(1):51-62.
49. Findling RL, Frazier JA, Gerbino-Rosen G, Kranzler HN, Kumra S, **Kratochvil CJ** (2007). Is there a role for clozapine in the treatment of children and adolescents? J Am Acad Child Adolesc Psychiatry 46(3):423-428

50. Gonzalez-Heydrich J, Weiss M, Connolly M, Wambera K, Jan JE, Plioplys S, Dunn DW, **Kratochvil CJ** (2006). Pharmacological Management of a Youth with ADHD and a Seizure Disorder. J Am Acad Child Adolesc Psychiatry 45(12):1527-1532.
51. Vaughan B, **Kratochvil CJ** (2006). Pharmacotherapy of ADHD in Young Children. Psychiatry 2006.
52. Madaan V, Kinnan S, Daughton J, **Kratochvil CJ** (2006). Innovations and Recent Trends in the Treatment of ADHD: A Review. Expert Review of Neurotherapeutics 6(9):1375-1385
53. **Kratochvil CJ**, Emslie GJ, Silva SG, McNulty S, Walkup J, Curry J, Reinecke MA, Vitiello B, Rohde P, Feeney NC, Casat C, Pathak S, Weller E, May D, Mayes TL, Robins M, March JS and the TADS Team (2006). Acute Time to Response in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 45(12):1412-1418
54. Newcorn JH, Michelson D, **Kratochvil CJ**, Allen AJ, Ruff DD, Moore RJ and the Atomoxetine Study Group (2006). Low-dose Atomoxetine for Maintenance Treatment of ADHD. Pediatrics. 118(6):e1701-1706
55. Deupree JD, Smith SD, **Kratochvil CJ**, Bohac D, Ellis CR, Polaha J and Bylund DB (2006) Possible Involvement of Alpha-2A Adrenergic Receptors in Attention Deficit Hyperactivity Disorder: Radioligand Binding and Polymorphism Studies. Am J Med Genetics Part B (Neuropsychiatric Genetics). 141B877-884.
56. Sankaranarayanan JM.Pharm, Puumala SE, **Kratochvil, CJ** (2006). Diagnosis and Treatment of Adult Attention-Deficit/Hyperactivity Disorder in US Ambulatory Care from 1996 to 2003. Current Medical Research and Opinion. 22(8):1475-1491.
57. **Kratochvil CJ**, Wilens TE, Upadhyaya H (2006). Pharmacological Management of a Youth with ADHD, Marijuana Use, and Mood Symptoms. J Am Acad Child Adolesc Psychiatry 45(9):1138-1141.
58. Emslie GJ, **Kratochvil CJ**, Vitiello B, Silva SG, Mayes TL, McNulty S, Weller E, Waslick B, Casat C, Walkup J, Pathak S, Rohde P, Posner K, March J, Columbia Suicidality Classification Group and the TADS Team (2006). Treatment for Adolescents with Depression Study (TADS): Safety Results. J Am Acad Child Adolesc Psychiatry 45(12):1440-1455.
59. Kennard BD, Silva SG, Vitiello B, Curry J, **Kratochvil CJ**, Simons A, Hughes JL, Feeny N, Weller EB, Sweeney M, Reinecke M, Pathak S, Ginsburg GS, Emslie GJ, March J, and the TADS Team (2006). Remission and Residual Symptoms after Acute Treatment of Adolescents with Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 45(12):1404-1411.
60. March JS, Silva SG, Vitiello B, and the TADS Team (2006). The Treatment for Adolescents with Depression Study (TADS): Methods and Message at Twelve Weeks. J Am Acad Child Adolesc Psychiatry 45(12):1393-1403.
61. Vitiello B, Rohde P, Silva SG, Wells KC, Casat C, Waslick B, Simons A, Reinecke MA, Weller E, **Kratochvil CJ**, Walkup J, Pathak S, Robins M,

- March J, and the TADS Team (2006). Effects of Treatment on Level of Functioning, Global Health, and Quality of Life in Depressed Adolescents. J Am Acad Child Adolesc Psychiatry 45(12):1419-1426.
62. Curry JF, Rohde P, Simons A, Silva SG, Vitiello B, **Kratochvil CJ**, Reinecke MA, Feeny N, Wells KC, Pathak S, Weller E, Rosenberg D, Kennard BD, Robins M, Ginsburg GS, March JS, and the TADS Team (2006). Predictors and Moderators of Acute Outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 45(12):1427-1439.
63. **Kratochvil CJ**, Kazura A, Deas D, Martin CA, Dosh T, Wilens TE (2006). Pharmacological Management of a Teen with Significant Alcohol Use and Depression. J Am Acad Child Adolesc Psychiatry. 45(8): 1011-1015.
64. Perwien AR, **Kratochvil CJ**, Faries DE, Vaughan BV, Spencer T, Brown RT (2006). Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: What are the long-term health-related quality of life outcomes? J Child Adolesc Psychopharm. 16(6):713-724.
65. Wilens T, Newcorn J, **Kratochvil CJ**, Gao H, Thomason CK, Rogers AK, Feldman P, Levine L (2006). Long-term Atomoxetine Treatment in Adolescents with Attention-Deficit/Hyperactivity Disorder. J Pediatrics. 149(1): 118-125.
66. **Kratochvil CJ**, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL (2006). Effects of Long-term Atomoxetine Treatment for Young Children with Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 48(8): 919-927.
67. Brown RT, Perwien A, Faries DE, **Kratochvil CJ**, Vaughan BS (2006). Atomoxetine in the Management of Children with ADHD: Effects on Quality of Life and School Functioning. Clin Pediatr. 45(9):819-827
68. **Kratochvil CJ**, Varley C, Cummins TK, Martin A (2006). Less is More: Inpatient Management of a Child with Complex Pharmacotherapy. J Am Acad Child Adolesc Psychiatry 45(5):621-624.
69. Wilens TE, **Kratochvil CJ**, Newcorn J, Thomason C, Gao H (2006). Do Children and Adolescents with ADHD Respond Differently to Atomoxetine? J Am Acad Child Adolesc Psychiatry. 45:149-157.
70. **Kratochvil CJ**, Vitiello B, Walkup J, Emslie G, Waslick BD, Weller EB, Burke WJ, March JS (2006). SSRIs in Pediatric Depression: Is the Balance Between Benefits and Risks Favorable? J Child Adolesc Psychopharm. 16(1):151-164.
71. **Kratochvil CJ**, Vitiello B, Brent D, Bostic JQ, Naylor MW (2006). Selecting an Antidepressant for the Treatment of Pediatric Depression. J Am Acad Child Adolesc Psychiatry. 45(3):371-373.
72. **Kratochvil CJ**, March J, Prentice E (2006). Guidance for IRB's on Placebo and Alternatives to Placebo in Randomized Controlled Trials. The Bureau of National Affairs. 5(6):220-224.
73. Wilens T, McBurnett K, Buckstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Dwyer J, Newcorn J, Bailey CE, **Kratochvil CJ**,

- Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper K, Lynch JM (2006). A Multisite, Controlled Trial of OROS® Methylphenidate (CONCERTA®) in the Treatment of Adolescents with Attention-Deficit/Hyperactivity Disorder. Arch Ped Adolesc Med, 160:82-90.
74. **Kratochvil CJ**, Egger H, Greenhill LL, McGough (2006). Pharmacological Management of Preschool ADHD. J Am Acad Child Adolesc Psychiatry, 45(1):115-118.
75. Pathak S, **Kratochvil CJ**, Rogers GM, Silva S, Vitiello B, Weller EB, March JS (2005). Comparative Efficacy of Cognitive Behavioral Therapy, Fluoxetine, and Their Combination in Depressed Adolescents: Initial Lessons from the Treatment for Adolescents with Depression Study. Curr Psychiatry Rep, 7(6):429-434.
76. Biederman J, Swanson JM, Wigal SB, **Kratochvil CJ**, Boellner SW, Earl CQ, Jiang J, Greenhill LL (2005). Efficacy and Safety of Modafinil Film-Coated Tablets in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study. Pediatrics, 116(6):e777-84.
77. **Kratochvil CJ**, DelBello M, Upadhyaya H, Wozniak J (2005). Pharmacological Management of New-Onset Bipolar Disorder. J Am Acad Child Adolesc Psychiatry, 44(11):1198-1200.
78. **Kratochvil CJ**, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J (2005). Atomoxetine alone or combined with fluoxetine for treating ADHD and comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry, 44(9):915-924.
79. **Kratochvil CJ**, Findling RL, McDougale CJ, Scahill L, Hamarman S (2005). Pharmacological management of agitation and aggression in an adolescent with autism. J Am Acad Child Adolesc Psychiatry, 44(8):829-832.
80. **Kratochvil CJ**, Simons A, Vitiello B, Walkup J, Emslie G, Rosenberg D, March JS (2005). A multi-site psychotherapy and medication trial for depressed adolescents: Background and benefits. Cognitive and Behavioral Practice, 12:159-165.
81. Ginsburg GS, Albana AM, Findling RL, Walkup J, **Kratochvil C** (2005). Integrating cognitive behavioral therapy and pharmacotherapy in the treatment of adolescent depression. Cognitive and Behavioral Practice, 12:252-262.
82. Weiss M, Tannock R, **Kratochvil C**, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ (2005). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry, 44(7):647-655.
83. **Kratochvil CJ**, Lake M, Pliszka SR, Walkup JT (2005). Psychopharmacology perspectives: Pharmacological management of treatment-induced insomnia in ADHD. J Am Acad Child Adolesc Psychiatry, 44(5):499-501.

84. Spencer T, Newcorn J, **Kratochvil C**, Ruff D, Michelson D, Biederman J (2005). Effects of atomoxetine on growth after 2-year treatment in pediatric patients with ADHD. Pediatrics 116(1):e74-e80.
85. Polaha J, Cooper S, Meadows T, **Kratochvil C** (2005). The assessment of attention-deficit/hyperactivity disorder in rural primary care: The portability of the American Academy of Pediatrics guidelines to the 'real world.' Pediatrics 115(2):e120-6.
86. **Kratochvil CJ**, Dineen Wagner K, Emslie G, March J (2005). Pharmacological management of treatment-resistant pediatric depression. J Am Acad Child Adolesc Psychiatry, 44(2):198-200.
87. Treatment for Adolescents with Depression Study (TADS) Team (2005). The treatment for adolescents with depression study (TADS): Demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry, 44(1):28-40.
88. **Kratochvil CJ**, Greenhill LL, March JS, Burke WJ, Vaughan BS (2004). The role of stimulants in the treatment of preschool children with attention-deficit hyperactivity disorder. CNS Drugs, 18(14):957-966.
89. Treatment for Adolescents with Depression Study (TADS) Team (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. Journal of the American Medical Association, 292:807-820.
90. **Kratochvil CJ**, Vaughan BS, Daughton JM, Mayfield-Jorgensen ML, Burke WJ (2004). Atomoxetine in the treatment of attention deficit hyperactivity disorder. Expert Rev Neurotherapeutics, 4(4):601-611.
91. March J, **Kratochvil C**, Clarke G, Beardslee W, Derivan A, Emslie G, Green EP, Heiligenstein J, Hinshaw S, Hoagwood K, Jensen P, Lavori P, Leonard H, McNulty J, Michaels A, Mossholder A, Osher T, Petti T, Prentice E, Vitiello B, Wells K (2004). AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric pharmacology. Journal of the American Academy of Child & Adolescent Psychiatry, 43(8):1046-1056.
92. Hinshaw SP, Hoagwood K, Jensen PS, **Kratochvil C**, Bickman L, Clarke G, Abikoff HB, Atkins M, Vitiello B (2004). AACAP 2001 research forum: challenges and recommendations regarding recruitment and retention of participants in research investigations. Journal of the American Academy of Child & Adolescent Psychiatry, 43(8):1037-1045.
93. Matza LS, Rentz AM, Swensen AR, Secnik K, Revicki DA, Michelson D, Spencer T, Newcorn J, **Kratochvil CJ** (2004). The link between health-related quality of life and clinical symptoms in children with ADHD. Journal of Developmental and Behavioral Disorders, 25(3):166-174.
94. Perwien AR, Faries DE, **Kratochvil CJ**, Sumner CR, Kelsey DK, Allen AJ (2004). Improvement in health-related quality of life in children with ADHD: an analysis of placebo-controlled studies of atomoxetine. Journal of Developmental and Behavioral Pediatrics, 25(4):264-271.

95. Lowe N, Kirley A, Hawi Z, Sham P, Wickham H, **Kratochvil CJ**, Smith SD, Lee SY, Levy F, Kent L, Middle F, Rohde LA, Roman T, Tahir E, Yazgan Y, Asherson P, Mill J, Thapar A, Payton A, Todd RD, Stephens T, Ebstein RP, Manor I, Barr CL, Wigg KG, Sinke RJ, Buitelaar JK, Smalley SL, Nelson SF, Biederman J, Faraone SV, Gill M (2004). Joint analysis of DRD5 marker concludes association with ADHD confined to the predominantly inattentive and combined subtypes. American Journal of Human Genetics, 74:348-356.
96. **Kratochvil CJ**, Vaughan BS, Harrington MJ, & Burke WJ (2003). Atomoxetine: a selective norepinephrine reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Pharmacology, 4:1165-1174.
97. **Kratochvil CJ**, Harrington MJ, Burke WJ, & Vaughan BS (2003). Atomoxetine: treatment of attention-deficit/hyperactivity disorder through selective norepinephrine reuptake inhibition. Today's Therapeutic Trends, 21:239-250.
98. Biederman J, **Kratochvil CJ**, Spencer TJ, & Wozniak J (2003). Determining and achieving therapeutic targets in attention-deficit/hyperactivity disorder. Academic Highlights section of Journal of Clinical Psychiatry, 64:265-276.
99. The Treatment of Adolescent Depression Study (TADS) Team (2003). Treatment for adolescents with depression study (TADS): rationale, design and methods. Journal of the American Academy of Child & Adolescent Psychiatry, 42:531-542.
100. Greenhill LL, Jensen PS, Abikoff H, Blumer JL, DeVeau-Geiss J, Fisher C, Hoagwood K, **Kratochvil CJ**, Lahey BB, Laughren T, Leckman J, Petti TA, Pope K, Shaffer D, Vitiello B, & Zeanah C (2003). Developing strategies for psychopharmacological studies in preschool children. Journal of the American Academy of Child & Adolescent Psychiatry, 42:406-414.
101. Biederman J, Heiligenstein J, Faries D, Galil N, Dittman R, Emslie GJ, **Kratochvil C**, Laws H, Schuh KJ, & the Atomoxetine Study Group (2002). Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics, 110(6). URL: <http://www.pediatrics.org/cgi/content/full/110/6/e75>.
102. Spencer JT, Heiligenstein JH, Biederman J, Faries DE, **Kratochvil CJ**, Conners CK, & Potter WZ (2002). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 63:1140-1147.
103. Wernicke JF & **Kratochvil, CJ** (2002). Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Journal of Clinical Psychiatry, 63[suppl 12]:50-55.
104. **Kratochvil CJ**, Harrington MJ, Burke WJ, March JS (2002). Pharmacotherapy of childhood anxiety disorders. Current Psychiatric Reports, 4:264-269.

105. Michelson D, Allen AJ, Kelsey D, Busner J, Casat C, Dunn D, **Kratochvil C**, Newcorn J, Sallee FR, Sangal RB, Saylor K, West D, Wernicke J, Raute N, & Harder D (2002). Safety and efficacy of once-daily atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder. American Journal of Psychiatry, 159:1896-1901.
106. Burke WJ, **Kratochvil CJ** (2002). Stereoisomers in psychiatry. The case of escitalopram. Primary Care Companion to the Journal of Clinical Psychiatry. 4(1):20-24.
107. **Kratochvil C**, Heiligenstein J, Spence T, Biederman J, Wernicke J, Newcorn J, Casat C, & Michelson D (2002). Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. Journal of the American Academy of Child & Adolescent Psychiatry, 41(7):776-784.
108. Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Jacobson JG, and the Fluoxetine Pediatric OCD Study Team (2001). Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. Journal of the American Academy of Child & Adolescent Psychiatry, 40(7):773-779.
109. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, & the Atomoxetine Study Group (2000). Atomoxetine in the treatment of children with ADHD: a randomized, placebo-controlled dose response study. Pediatrics. 108 (5) e83.
110. **Kratochvil CJ**, Bohac D, Harrington M, Baker N, May D, & Burke WJ (2001). An open-label trial of atomoxetine in pediatric ADHD. Journal of Child and Adolescent Psychopharmacology. 11 (2):167-170.

Book Edited

1. Pediatric Psychopharmacology: Principles and Practice, 2nd Edition, Martin A, Scahill L, Kratochvil CJ Editors, Oxford Press, 2011.


Book Chapters

1. Daughton J, Kratochvil CJ. Stimulants. In Pediatric Psychopharmacology: Principles and Practice, 2nd Edition. Edited by Martin, Scahill and Kratochvil; Oxford Press, 2011.
2. Carandang CG, Kratochvil CJ, Scahill L, Martin A. Running a Pediatric Psychopharmacology Clinic: Practical Aspects. In Pediatric Psychopharmacology: Principles and Practice, 2nd Edition. Edited by Martin, Scahill and Kratochvil; Oxford Press, 2011.
3. Kratochvil CJ, Wells K, March JS. Combining Pharmacotherapy and Psychotherapy: An Evidence-based Approach. In Pediatric Psychopharmacology: Principles and Practice, 2nd Edition. Edited by Martin, Scahill and Kratochvil; Oxford Press, 2011.
4. Dell ML, Vaughan BS, Kratochvil CJ. Ethical Issues in Pediatric Psychopharmacology Research. In Pediatric Psychopharmacology:

- Principles and Practice, 2nd Edition. Edited by Martin, Scahill and Kratochvil; Oxford Press, 2011.
5. Brent DA, Stark KD, Kratochvil CJ. I Just Want to Die: Double Depression. In DSM-IV-TR Casebook and Treatment Guide for Child Mental Health. Edited by Galanter CA & Jensen PS; American Psychiatric Publishing, 2009; pp. 403-418.
 6. Kratochvil CJ and Wetzel M. Attention-Deficit/Hyperactivity Disorder. In Conn's Current Therapy 2009. Edited by Rakel RE & Bope E; Saunders, Elsevier, 2009; pp. 916-918.
 7. Kratochvil CJ, Prentice ED, Gordon BG, & Kotulak GD. Regulatory Issues of Research Involving Prisoners. In Institutional Review Board: Member Handbook, Second Edition. Edited by Andur RJ & Bankert EA; Jones & Bartlett Publishers, 2007; pp. 181-185.
 8. Gordon BG, Brown J, Kratochvil C, Prentice ED & Amdur RJ. Paying Research Subjects. In Institutional Review Board: Member Handbook, Second Edition. Edited by Andur RJ & Bankert EA; Jones & Bartlett Publishers, 2007; pp.107-113.
 9. Kratochvil CJ, Prentice ED, Epperson KJ, Gordon BG. Institutional Review Board Review of Adverse Events. In Institutional Review Board: Management and Function, Second Edition. Edited by Bankert EA and Amdur RJ; Jones & Bartlett Publishers, 2007; 257-261.
 10. Kratochvil C. Contributing author (questions and text). Study Guide for Institutional Review Board Management and Function. Edited by Davis AL, Bankert EA, Hansen K, Kornetsky S, McGough H; Jones & Bartlett Publishers, 2006.
 11. Kratochvil, C., Harrington, M. Adolescent Interpersonal Relationships. In Textbook of Adolescent Psychiatry. Edited by Richard Rosen: Arnold, London, 2003; pp. 193-198.
 12. Kratochvil, C. Contributing author (questions and text). Study Guide for Institutional Review Board: Management and Function. Edited by Kornetsky S, Davis A, & Amdur RJ; Jones & Bartlett Publishers, 2002.
 13. Gordon B, Brown J, Kratochvil CJ, & Prentice E: Paying research subjects. In Institutional Review Board: Member Handbook. Edited by Andur R; Jones & Bartlett Publishers, 2002; pp.105-112.
 14. Prentice ED, Gordon BG, Kratochvil CJ, & Kotulak GD: Research involving prisoners. In Institutional Review Board: Member Handbook. Edited by Andur R; Jones & Bartlett Publishers, 2002; pp. 171-174.
 15. Prentice ED, Epperson KJ, Kratochvil CJ, & Gordon B: IRB review of adverse events. In Institutional Review Board: Management and Function. Edited by Andur R and Banker E; Jones & Bartlett Publishers, 2002; pp.297-302.
 16. Gordon B, Brown J, Kratochvil CJ, & Prentice E: Paying research subjects. In Institutional Review Board: Management and Function. Edited by Andur R and Banker E; Jones & Bartlett Publishers, 2002; pp.185-190.

17. Prentice ED, Gordon BG, Kratochvil CJ, & Kotulak GD: Research involving prisoners. In Institutional Review Board: Management and Function. Edited by Andur R and Banker E,; Jones & Bartlett Publishers, 2002; pp. 394-398.
18. Kratochvil C, Kutcher S, Reiter S & March JS: Psychopharmacology of pediatric anxiety disorders. In Handbook of Psychotherapies with Children and Families. Edited by Ollendick TH and Russ SW; NY, NY, Kluwer Academic/Plenum Publishers, 1999.

Abstracts and Preliminary Communications

1.  (b) (4)
2. Wilson, T.W., Wetzel, M.W., White, M.L., May, D.E., Franzen, J., Knott, N.L., Kratochvil, C.J. Abnormal gamma-frequency neuronal responses in ADHD: Evidence from MEG imaging. Presented at the 66th Annual Meeting of the Society of Biological Psychiatry (SoBP), San Francisco, CA, May, 2011. *Biological Psychiatry (Suppl.)*, 69:45S-46S.
3. Franzen, J., May, D.E., Knott, N.L., Kratochvil, C.J., & Wilson, T.W. Increased resting-state gamma-frequency activity in the anterior cingulate and frontal regions in adolescents with attention-deficit/hyperactivity disorder. Presented at the 66th Annual Meeting of the Society of Biological Psychiatry (SoBP), San Francisco, CA, USA, May, 2011. *Biological Psychiatry (Suppl.)*, 69:44S.
4. Wilson, T.W., May, D.E., Knott, N.L., & Kratochvil, C.J. Children with ADHD exhibit reduced attention-based modulation of auditory cortical responses. Presented at the 17th International Conference on Biomagnetism, Dubrovnik, Croatia, 2010. *Frontiers in Neuroscience* (abstract): *Biomag 2010*. doi:10.3389/conf.fnins.2010.06.00298
5. Humble C, Jensen P, Wegner L, Wegner S, Kratochvil C, Stiles A. Enhancing pediatric psychopharmacology for ADHD in North Carolina's Medicaid program. Accepted, Annual Research Meeting of AcademyHealth, Boston, MA, June 2010.
6. Humble C, Newton T, Domino M, Jensen P, Wegner L, Stiles A, Kratochvil C, Wegner S. Optimizing pediatric psychopharmacology for ADHD in North Carolina. Annual Research Meeting of American Public Health Association, Denver, CO, November 2010.
7. Wegner L, Jensen P, Kratochvil C, Humble C, Wegner S, , Stiles A. Enhancing resident physician training in pediatric psychopharmacology for ADHD. Annual Research Meeting of Academy Health, Seattle, WA, June 2011.
8. Gault LM, Apostol G, Wilens TE, Kratochvil CJ, Robieson WZ, Hall CM, Abi-Saab WM, Saltarelli MD. Safety and Efficacy of ABT-089, a Novel Neuronal Nicotinic Receptor Partial Agonist, in the Treatment of

- Children with ADHD. March JS, Emslie GJ, Kratochvil CJ, Pangallo BA, Lobo E, Tamura RN, Kogut S, Quinlan T, Prakash A. Annual Meeting of the AACAP, Honolulu, Hawaii, October 26-November 1, 2009
9. Daughton JM, Vaughan B, Barker A, Kratochvil CJ. Long-Acting Stimulant Treatment of ADHD in Young Children. Annual Meeting of the AACAP, Honolulu, Hawaii, October 26-November 1, 2009
 10. An Open-label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in Children (7-11 years) and Adolescents (12-17 years) with Major Depressive Disorder. 49th Annual NCDEU Meeting, Hollywood, FL, June 29-July 2, 2009.
 11. Connor DF, Spencer T, Kratochvil C, Lopez FA, Lyne A, Tremblay G. Effects of Guanfacine Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms. Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 16-21, 2009.
 12. Kratochvil CJ, Vaughan B, Daughton J, Lubberstedt B, Murray D, Chrisman A, Faircloth M, Itchon-Ramos N, March JS, Maayan LA, Greenhill LL, Kotler LA, Fried JE, Stoner J. Atomoxetine vs. Placebo for the Treatment of ADHD in 5- and 6-Year-Old Children. Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008
 13. Farmer JB, Murray D, Ravi H, Faircloth M, Kratochvil CJ, Vaughan B, Daughton J, Maayan JL, Kotler JA, Jorgensen M, Strauss T. The Clinical Implications of an Innovative Service Delivery Model for ADHD: Combining Parent Education with Medication Management. Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008
 14. Apostol G, Adler LA, Abi-Saab W, Wilens TE, Kratochvil CJ, Robieson WZ, Wozniak PJ, Saltarelli M. Patient-Reported and Overall Clinical Improvement Associated with ABT-089 in Adult ADHD. Annual Meeting of the American Psychiatric Association, Washington D.C., May 308, 2008
 15. Abi-Saab W, Wilens TE, Apostol G, Kratochvil CJ, Robieson WZ, Pritchett YL, Collins MA, Saltarelli M. Efficacy and Safety of ABT-089 in Adults with Attention-Deficit/Hyperactivity Disorder. Annual Meeting of the American Psychiatric Association, Washington D.C., May 308, 2008
 16. Moore CK, Moore RJ, Zdon G, Sutton VK, Kratochvil CJ, Schaeffer J, Riordan HJ. 6-Year Prescribing Trends for Antidepressants in the Pediatric Population. 4th Annual Meeting of the International Society for CNS Clinical Trials and Methodology (ISCTM); Washington, DC; February 25-27, 2008
 17. Spencer TJ, Kratochvil CJ, Sangal R, Saylor K, Bailey C, Dunn D, Casat C, Lipetz R, Jain R, Newcorn J, Ruff D, Feldman P, Allen A. Five-Year Effects of Atomoxetine on Growth in Children with ADHD. 13th International Congress of the European Society for Child & Adolescent Psychiatry (ESCAP); Florence, Italy; August 25-29, 2007
 18. Kratochvil CJ, Vaughan BS, Mayfield-Jorgensen ML, March JS, Kollins SH, Ravi H, Greenhill LL, Kotler LA, Paykina N, Biggins P, Stoner J. A

- Pilot Study of Atomoxetine in Young Children with ADHD. Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006
19. Thomason CK, Riordan HJ, Schaeffer JA, Slagle PK, Cox K, Kratochvil CJ. Antidepressant Prescribing Practices Prior to and After the Black Box Warning. Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006
 20. Spencer TJ, Kratochvil CJ, Sangal R, Saylor K, Bailey C, Dunn D, Casat C, Lipetz R, Jain R, Newcorn J, Ruff D, Feldman P, Allen A. Five-Year Effects of Atomoxetine on Growth in Children with ADHD. Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006
 21. Lerner M, Wigal SB, Kratochvil CJ, Jiang JG, Earl CQ. Effects of Modafinil in Previously Untreated Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Annual Meeting of the American Academy of Pediatrics, Atlanta, GA, October 7-10, 2006
 22. Spencer TJ, Kratochvil, CJ, Ruff DD, Feldman PD. Examination of Methods for Evaluating and Monitoring Growth in ADHD Children: Limitations and Expectations. 17th International Congress of the International Association for Child & Adolescent Psychiatry & Allied Professions, Melbourne, Australia, September 10-14, 2006.
 23. Sankaranarayanan J, Puumala SE, Kratochvil CJ. Medication and Behavioral Treatment of Adult Attention-Deficit/Hyperactivity Disorder in United States Ambulatory Care from 1996 to 2003. Academy Health 2006 Annual Research Meeting, Seattle, Washington, June 26, 2006.
 24. Kratochvil CJ, Spencer TJ, Ruff DD, Moore RJ, Gaillez C, Allen AJ. Long-term Effects of Atomoxetine on Growth in Children with ADHD. Annual Meeting of the Society of French Pediatricians, June 14-17, 2006 Lyon, France.
 25. Wigal SB, Kratochvil CJ, Pliszka SR, Arnold V, Knutson JA, Boellner SW, Earl CQ, Yang R, Jiang JG. Modafinil-ADHD in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Efficacy and Tolerability is Maintained with Long-term Treatment. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 12-15, 2006.
 26. Thomason C, Riordan H, Schaeffer J, Cox K, Kratochvil C. A Review of Antidepressant Prescribing Practices in a Large, National, Managed Care Database of Pediatric Patients Prior to and After Black-Box Warnings. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 12-15, 2006.
 27. Madaan V, Kratochvil CJ, Puubala S, May D, March J. Impact of Attention-Deficit/Hyperactivity Disorder on the Treatment of Depressed Adolescents. Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006.
 28. Vaughan BS, Faries DE, Kratochvil CJ, Perwien A, Brown R. Health-Related Quality of Life, Social Skills and Academic Functioning in School-Aged Children with ADHD. 19th Annual Conference of the American Psychiatric Nurses Association, Nashville, TN, November 2-5, 2005.

29. Kratochvil C, Biederman J, Swanson JM, Greenhill L, Earl CQ, Jiang JG. Efficacy of Modafinil Film-coated Tablets (Modafinil-ADHD) in Attention-Deficit/Hyperactivity Disorder Established in Three Randomized Controlled Trials. 17th Annual International Conference on Attention-Deficit/Hyperactivity Disorder, Dallas, TX, October 27-29, 2005.
30. Bhatia SK, Kratochvil CJ, Vitiello B, Sitorius MA, Buehler BA, Rezac AJ. Pediatric Mental Health Resources and Antidepressant Prescribing Practices. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
31. Wilens T, Kratochvil C, Newcorn J, Gao H. Acute Effects of Atomoxetine in Children versus Adolescents. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
32. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason C, Rogers AK, Feldman PD, Levine LR. Effects of Longer-Term Atomoxetine Treatment in Adolescents with ADHD. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
33. Kratochvil CJ, Faries DE, Vaughan BS, Perwien AR, Busner J, Saylor K, Kaplan S, Buermeyer C, Saylor D, Swindel R. Emotional Expression During ADHD Treatment: Initial Assessment of Treatment Effects. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
34. Kratochvil CJ, Michelson D, Newcorn JH, Moore RJ, Ruff DD, Dickson R, Saylor K, Busner J, Luber S, Turgay A, Weiss M, Vaughan B, Allen AJ. High-Dose Atomoxetine for the Treatment of ADHD. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
35. Biederman J, Wigal S, Kratochvil C, Swanson J, Greenhill L. Modafinil Film-Coated Tablets Improve Symptoms of Attention-Deficit/Hyperactivity Disorder. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
36. Newcorn JH, Kratochvil CJ, Allen AJ, Ruff DD, Zhang S, Moore RJ, Michelson D. Low-Dose Atomoxetine for Maintenance Treatment of ADHD. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
37. Kratochvil CJ, Greenhill LL. Safety and Tolerability of Modafinil in Children and Adolescents with ADHD. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
38. Newcorn JH, Kratochvil CJ, Allen AJ, Milton DR, Moore RJ, Michelson D. Atomoxetine and OROS Methylphenidate for the Treatment of ADHD: Acute Results and Methodological Issues. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 6-9, 2005.

39. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Greenhill LL, Earl CQ, Jiang JG. Safety and Efficacy of Modafinil Film-Coated Tablets in Children and Adolescents with ADHD. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 6-9, 2005.
40. Kratochvil CJ, Spencer TJ, Ruff DD, Moore RJ, Allen AJ. Long-term Effects of Atomoxetine on Growth in Children with ADHD. Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington D.C., October 19-24, 2004.
41. Kratochvil CJ, Perwien A, Vaughan B, Faries D, Saylor K, Busner J, Bermire C, Wong H, Swindle R. Emotional Expression and ADHD Pharmacotherapy in Children: A New Measure. Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington D.C., October 19-24, 2004.
42. Kratochvil CJ, Greenhill LL, Gao H, Thomason CK, and Gelowitz DL. Long-term Atomoxetine Administration for Young Children with Attention-Deficit/Hyperactivity Disorder. Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, D.C., October 19-24, 2004.
43. Vaughan BS, Faries DE, & Kratochvil C (2004). Health Related Quality of Life in Children with ADHD: Long Term Effects of Atomoxetine. Annual Meeting of the American College of Nurse Practitioners, Philadelphia, PA, October 20-23, 2004.
44. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Dickson R, and Gelowitz DL. 54th Annual Meeting of the Canadian Psychiatry Association, October 14-17, 2004, Montréal, Quebec Do Children and Adolescents with ADHD Respond Differently to Atomoxetine?
45. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Weiss M, Greenhill LL, Gao H, Weiss M, and Gelowitz DL. Canadian Academy of Child and Adolescent Psychiatry Meeting Montreal, Quebec, October 3- 5, 2004, Effects of Long-term Atomoxetine Treatment for Young Children with ADHD.
46. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Weiss M, Greenhill LL, Gao H, Weiss M, and Gelowitz DL. Effects of Long-term Atomoxetine Treatment for Young Children with ADHD. 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, Berlin Germany, August 22-26, 2004.
47. Simpson A, Kratochvil CJ, Newcorn JH, Allen AJ, Faries DE, Zhang S, Milton DR, Feldman PD, Schuh KJ, Michelson D, Biederman J. Efficacy of atomoxetine in placebo-controlled studies in children, adolescents, and adults with attention-deficit/hyperactivity disorder. 12th Congress of the Association of European Psychiatrists, Geneva, Switzerland, April 14-18, 2004.
48. Wilens TE, Newcorn J, Kratochvil C, Gelowitz D, Thomason C, Rogers AK. Longer-Term Treatment with Atomoxetine in Adolescents with ADHD. Annual Meeting of the American Psychiatric Association, New York City, NY, May 1-6, 2004.

49. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Thomason CK & Gelowitz DL. Effects of long-term atomoxetine treatment for young children with ADHD. Annual Meeting of the American Psychiatric Association, New York City, NY, May 1-6, 2004.
50. Kratochvil CJ, Greenhill LL, Milton DR, Gelowitz DL, Rogers AK. Acute effects of atomoxetine in different pediatric age categories: a comparative analysis. 59th Annual Meeting of the Society of Biological Psychiatry, New York City, NY, April 29-May 1, 2004.
51. Bylund DB, Deupree JD, Kratochvil CJ, Smith SD, Ellis CR. Alpha-2 adrenergic receptors in attention deficit hyperactivity disorder (ADHD). Experimental Biology 2004, Washington D.C., April 18, 2004.
52. Kratochvil CJ, Newcorn J, Gao H, Michelson D. Atomoxetine for comorbid ADHD and affective symptoms. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.
53. Kratochvil CJ, Milton DR, Vaughan BS, Burke WJ, Jones ED. Atomoxetine in the treatment of young children with ADHD. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.
54. M. Weiss, R Tannock, C Kratochvil, D Dunn, J Velez-Borras, C Thomason, L Lambrecht, R Tamura, D Kelsey, and AJ Allen. Controlled study of once-daily atomoxetine in the school setting. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.
55. Wilens T, McGough J, Kratochvil C, on behalf of the Adolescent Study Group. Tolerability of OROS methylphenidate (MPH) in adolescents with ADHD. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.
56. Perwein AR, Faries D, Kratochvil C, Michelson D: Long-term effects of atomoxetine on health-related quality of life. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.
57. Perwein AR, Faries D, Kratochvil C, Sumner C, Kelsey D, Allen A. Functional outcomes and ADHD: the effect of atomoxetine treatment. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.
58. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Lambrecht L, Tamura R, Kelsey D, Allen, AJ. Placebo-controlled study of once daily atomoxetine in the school setting. European Society of Child and Adolescent Psychiatry; Paris, France; September 28 – October 1, 2003.
59. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Lambrecht L, Tamura R, Kelsey D, Allen, AJ. Placebo-controlled study of once daily atomoxetine in the school setting. European College of Neuropsychopharmacology; Prague, Czech Republic; September 20-24, 2003.

60. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Lambrecht L, Tamura R, Kelsey D, & Allen AJ. Controlled study of once-daily atomoxetine in the school setting. Canadian College of Neuropsychopharmacology; Montreal, CA; June 1-4, 2003.
61. Kratochvil CJ, Milton D, Vaughan V, & Burke WJ: Atomoxetine in the treatment of young children with ADHD. New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, May 28, 2003.
62. Kratochvil CJ: A Randomized, Placebo-Controlled Study of Once-Daily Atomoxetine in the School Setting in Children with ADHD. 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 20, 2003.
63. Michelson D, Allen AJ, Kelsey D, Kratochvil C, Newcorn J, Wernicke J: Once-daily atomoxetine treatment for children and adolescents with ADHD. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, San Francisco, CA, October 22-23, 2002.
64. Wernicke JF, Kratochvil C, Michelson D, Milton D, Dunn D, Spencer T, Heiligenstein J: Long-term safety of atomoxetine in the treatment of ADHD. World Psychiatric Congress, Yokohama, Japan, July 17, 2002.
65. Burke WJ, Frank MG, Ranno AE, McArthur-Miller DA, Johnson Dr, Kratochvil CK: A randomized, placebo-controlled trial of citalopram's effect on natural killer cell activity in major depression. NCDEU 42nd Annual Meeting, Boca Raton, FL, June 10-13, 2002.
66. Vaughan BV, Kratochvil C, Bohac D, & Burke W: Relationship between compliance and long-term efficacy of atomoxetine treatment: One year data. Nebraska Nurse Practitioner 11th Annual Primary Care Conference, Kearney, NE, February 21-23, 2002.
67. Kratochvil CJ, Heiligenstein J, Dittman R, Spencer T, Biederman J, Wernicke J, Newcorn J, Casat C, Milton D, & Michelson D: Atomoxetine and methylphenidate treatment in ADHD children: a randomized open-label trial. Scientific Proceedings of the 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu HI, October 25, 2001.
68. Kratochvil CJ, Michelson D, Wernicke J, Heiligenstein J, Spencer T, Allen AJ, Faries D, & Kendrick K: Atomoxetine: a new, non-dopaminergic intervention for ADHD. Scientific Proceedings of the 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI, October 25, 2001.
69. Kratochvil, CJ, Wernicke J, Michelson D, Vaughan B, Bohac D, Harrington M, Baker N, May D, & Burke W: Long-term study of atomoxetine in the treatment of ADHD. Scientific Proceedings of the 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI, October 25, 2001.
70. Heiligenstein J, Biederman J, Faries D, Galil N, Dittman N, Emslie G, Kratochvil C, Laws H, & West S: Atomoxetine efficacy vs placebo in school-age girls with ADHD. Scientific Proceedings of the 48th Annual

- American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI, October 25, 2001.
71. Kratochvil CJ: ADHD Inside and Outside the Classroom Symposium; Expanding Treatment Options for ADHD. American Academy of Pediatrics, San Francisco, CA, October 21, 2001.
72. Kratochvil CJ, Vaughan B, Bohac D, Harrington MJ, Baker N, May D, & Burke WJ: Long-term efficacy of tomoxetine for pediatric ADHD: 1 year data. Scientific Proceedings of the 41st Annual NCDEU Meeting, Phoenix AZ, May 29, 2001.
73. Heiligenstein JH, Spencer TJ, Faries DE, Beiderman J, Kratochvil C, & Connors CK: Efficacy of atomoxetine vs. placebo in pediatric outpatients with ADHD. Scientific Proceedings of the 47th Annual American Academy of Child & Adolescent Psychiatry Meeting, NY, NY, October 26, 2000.
74. Kratochvil CJ, Harrington M, Baker N, Bohac D, May D, & Burke W: A open-label trial of atomoxetine in pediatric ADHD. Scientific Proceedings of the 47th Annual American Academy of Child & Adolescent Psychiatry Meeting, NY, NY, October 26, 2000.
75. Heiligenstein JH, Spencer TJ, Faries DE, Biederman J, Kratochvil C, Connors, CK: Efficacy of Tomoxetine vs. Placebo in Pediatric Outpatients with ADHD. Presented at American Academy of Child & Adolescent Psychiatry Annual Meeting, NY, NY, October 26, 2000
76. Kratochvil CK, Harrington M, Baker N, Bohac D, May D, Burke W: An Open Label Trial of Tomoxetine in Pediatric ADHD. Presented at American Academy of Child & Adolescent Psychiatry Annual Meeting, NY, NY, October 26, 2000

Book Reviews

- Kratochvil CJ (2008). Your Child in the Balance: An Insider's Guide for Parents to the Psychiatric Medicine Dilemma, Kalikow KT, CDS Books, Psychiatric Times, 25(3):66.
- Madaan V & Kratochvil CJ (2006). Attention Deficit Disorder: The Unfocused Mind in Children and Adults, Brown TE, Yale University Press, J Am Acad Child Adolesc Psychiatry, 45(12):.

Lay Press & Non-Peer Reviewed

- Lubberstedt B, Vaughan BS, Kratochvil CJ (2006) Treatment of Preschool ADHD: Overview of the Preschool ADHD Treatment Study (PATs). Child & Adolescent Psychopharmacology News
- Madaan V & Kratochvil CJ (2005). Hot Topics in ADHD: Pharmacology Update. Developmental and Behavioral News, 14(2): 6-7.
- Kratochvil CJ (2005). Understanding Phases of Drug Development. Attention! For Families & Adults with Attention-Deficit/Hyperactivity Disorder, 12(2):50-51.

National/International Symposia Chaired

- “Update on Pediatric Psychopharmacology”, Masters Course Session Chair, 164th Annual American Psychiatric Association Meeting, Honolulu, HI, May 14, 2011
- “Perspectives on Current Psychiatric Psychopharmacology Research Needs”, Research Forum, 57th Annual Meeting of the AACAP, New York, NY October 26-31, 2010
- “Update on Pediatric Psychopharmacology”, Masters Course Session Chair, 163rd Annual American Psychiatric Association Meeting, New Orleans, LA, May 22, 2010
- “Update on Treatment of ADHD in Adults”, Plenary Session Chair, 2nd International Congress on ADHD, Vienna, Austria, May 21-24, 2009
- “Practical Pediatric Psychopharmacology”, Symposia Co-Chair, Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008
- “Advanced Psychopharmacology Institute: Translating Recent Psychopharmacological Research Findings into Clinical Practice”, Symposia Co-Chair, Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008
- “Ethics Applications in Child & Adolescent Psychopharmacology Clinical Research and Practice”, Symposia Chair, New Clinical Drug Evaluation Unit, Phoenix, Arizona, May 29, 2008
- “Practical Pediatric Psychopharmacology”, Symposia Chair, Annual Meeting of the APA, Washington DC, May 2008
- “Practical Pediatric Psychopharmacology for the Primary Care Clinician”, Symposia Chair, Annual Meeting of the AACAP, Boston, MA, October, 2007
- “Comorbidity and Co-Medication in Children with ADHD and Other Child Psychiatric Disorder. A US American and Central European Perspective”, Co-Chair, 1st International Congress on ADHD, Wurzburg, Germany, June 2-5, 2007
- “Treatment of ADHD in Adults”, Co-Chair, 1st International Congress on ADHD, Wurzburg, Germany, June 2-5, 2007
- “Practical Pediatric Psychopharmacology for the Primary Care Clinician”, Symposia Chair, Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006
- “Advocating for Change Through Evidence-Based Medicine: A Focus on ADHD”, Symposium Chair, Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 21-24, 2006.
- “Clinical Perspectives on ADHD with Comorbidities”, Symposium Chair. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
- “Research Literacy: Speeding the Adoption of Evidence-Based Medicine (EBM) in Pediatric Psychiatry”, Co-Chair of Research Forum. Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
- Placebo and Alternatives to Placebo in Randomized, Controlled Trials in Pediatric Psychopharmacology.” Co-Chair of Research Forum. Annual

Meeting of the American Academy of Child & Adolescent Psychiatry, San Francisco, CA, October 22-23, 2002.

“New Approaches for Treating ADHD: The Whole Life Perspective.” Symposium Chair. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18-23, 2002.

“Pharmacotherapies in Young Children with ADHD.” Symposium Chair. Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18-23, 2002.

National/International Presentations

“Pediatric Psychopharmacology and Depression in Children & Adolescents”, 2011 Sino-American Symposium on Clinical and Translational Medicine, Shanghai China, June 24-26, 2011

“Pharmacotherapy for Children & Adolescents with ADHD”, 164th Annual American Psychiatric Association Meeting, Honolulu, HI, May 14, 2011

“ADHD Pharmacotherapy Update”, 15th Annual Psychiatric Update, University of Texas Medical Branch, Galveston, TX April 1, 2011

“Stimulant Research: Strengths, Limitations, and Potential Targets”, 57th Annual Meeting of the AACAP, New York, NY October 26-31, 2010

“Management of Pediatric Depression in a Primary Care Setting”, 57th Annual Meeting of the AACAP, New York, NY October 26-31, 2010

“Pharmacotherapy for Children & Adolescents with ADHD”, 163rd Annual American Psychiatric Association Meeting, New Orleans, LA, May 22, 2010

“Psychopharmacology: Practical Pediatric Management from Toddlers to Teens”, Annual Meeting of the American Academy of Pediatrics, Washington, DC, October 17-20, 2009

“Interventions and Psychopharmacology for the Primary Care Physician and the Developmental-Behavioral Specialist”, Annual Meeting of the American Academy of Pediatrics, Washington, DC, October 17-20, 2009

“Psychostimulant Treatment and Problems in Daily Care”, 2nd International Congress on ADHD, Vienna, Austria, May 21-24, 2009

“Update on Treatment of ADHD in Adults”, 2nd International Congress on ADHD, Vienna, Austria, May 21-24, 2009

“Depression in Children and Adolescents: Relevance of Recent Research to Clinical Practice”, University of Utah Kevin Finnegan, M.D. Memorial Grand Rounds, 2009

“Depression in Children and Adolescents: Relevance of Recent Research to Clinical Practice”, Yale Child Study Center, New Haven, CT, February 2009

“Principles of Psychopharmacology”, DB:PREP Intensive Review of Behavioral Pediatrics, Atlanta, GA, December 4-7, 2008

“Mood Disorders: Evaluation, Management and Treatment”, DB:PREP Intensive Review of Behavioral Pediatrics, Atlanta, GA, December 4-7, 2008

“A Double-Blind, Placebo-Controlled Study of Atomoxetine in Young Children with ADHD”, Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008

- “Pharmacological Challenges in the Treatment of ADHD with Comorbidity”, Annual Meeting of the AACAP, Chicago, IL, October 28-Nov 2, 2008
- “Depression in Children and Adolescents: Relevance of Recent Research to Clinical Practice”, 22nd Annual Biologic Basis of Pediatric Practice Symposium, Deer Valley Utah, September 7, 2008
- “Consensus Building to Generate Conflict of Interest Guidelines for Practitioners”, New Clinical Drug Evaluation Unit, Phoenix, Arizona, May 29, 2008
- “Minimizing Growth Effects of ADHD Medication in Clinical Practice”, APA Annual Meeting, Washington DC, May 9, 2008
- “Pediatric Psychopharmacology Case Discussions”, APA Annual Meeting, Washington DC, May 4, 2008
- “Pediatric Psychopharmacology,” NICHQ - Reaching Children Initiative Learning Collaborative, NY, NY, September 25, 2007
- The Treatment for Adolescents with Depression Study (TADS): Implications for Practice,” Children’s Hospital Medical Center, Cincinnati, Ohio, September 12, 2007
- “The Treatment for Adolescents with Depression Study (TADS): Implications for Practice,” University of Cincinnati, Cincinnati, Ohio, September 12, 2007
- “Evidence-based Treatment of ADHD”, University of Ulm, Ulm, Germany. June 6, 2007
- “Psychopharmacological Indications and Approaches”, 1st International Congress on ADHD, Wurzburg, Germany, June 2-5, 2007
- “Modafinil”, 1st International Congress on ADHD, Wurzburg, Germany, June 2-5, 2007
- “Minimizing Growth Effects of ADHD Medication in Clinical Practice”, 47th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 14, 2007
- “ADHD: Diagnostic Dilemmas & Controversies”, Annual Meeting of the American Psychiatric Association, San Diego California, May 23, 2007
- “Addressing Treatment of Special Groups: Preschool Children and Adults”, Annual Meeting of the American Psychiatric Association, San Diego, California, May 23, 2007
- “Comparison of Major Depressive Disorder and its Treatment in Children and Adults”, Experimental Biology 2007, Washington DC, April 28-May 2, 2007
- “Psychopharmacology in the Treatment for Adolescents with Depression Study (TADS)”, grand rounds, University of Texas San Antonio, March 27, 2007
- “ADHD Pharmacotherapy for Adolescents and Adults”, Improving Long-term Outcomes in ADHD: A Treatment Development Workshop, NIMH, Bethesda, MD, March 12-13, 2007
- “ADHD: An Office-Based Dilemma”, Annual Clinical Advances in Pediatrics Meeting, Children’s Mercy Health Network, Kansas City, MO, November 16, 2006
- “Research and Academic Psychiatry: The View from Nebraska”, Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006
- “Pharmacotherapy for Young Children with ADHD”, Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006

- “Psychopharmacology of ADHD in an Era of Regulatory Concern”, Annual Meeting of the AACAP, San Diego, CA, October 24-29, 2006
- “Adolescent Depression: Innovations in Evidence-Based Treatment”, The Mental Health Association of Franklin County & Ohio State University, Columbus Ohio, October 3, 2006
- “Update on the Pharmacological Management of ADHD in Children and Adolescents”, 9th Annual Clinical Pediatric Psychopharmacology State of the Art: Practical, sponsored by Albert Einstein College of Medicine & Montefiore Medical Center, New York, NY, September 15, 2006
- “Phenomenology and Diagnosis of ADHD”, Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 23, 2006
- “Treatment Effects on Remission Rates, Level of Functioning, Overall Health, and Quality of Life”, Annual Meeting of the Society of Biological Psychiatry, Toronto, Canada, May 19, 2006
- “Treatment for Adolescent Depression: FDA Hearings, Research Findings and Clinical Implications”, Psychiatry Grand Rounds, University of Utah, Salt Lake City, Utah, January 4, 2006.
- “A Research Career in Nebraska: Risks and Rewards”, NIH New Investigator Session, Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Toronto, Canada, October 18-23, 2005.
- “Medications for ADHD”, Annual Meeting of the American Academy of Pediatrics, Washington, D.C., October 8-11, 2005.
- “Pharmacotherapy for ADD/ADHD”, Psychopharmacology Update 2005, sponsored by Baylor College of Medicine & South Central VA MIRECC, Houston, Texas, October 15, 2005.
- “ADHD Symptoms and Behavior Improved with Modafinil Pediatric Formulation”, Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 23, 2005.
- “The Course of ADHD from Adolescence into Adulthood”, Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 24, 2005.
- “Large Observational Studies of ADHD: Methodology and Results”, Symposium Discussant, Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 24, 2005.
- “Pediatric Depression: Clinical Issues, Controversies and Current Research”, 9th Annual Practical Use of Psychiatric Medications, Billings, Montana, April 29, 2005
- “Pharmacotherapy of ADHD in Children & Adolescents”, Ste-Justine Hospital, Montreal, Canada, April 7, 2005
- “Pharmacotherapy of ADHD in Children & Adolescents”, Hotel Dieu Hospital, Kingston, Ontario, Canada, April 6, 2005
- “Nonstimulant Treatments: Overview of Acute and Long-term Efficacy”, 2004 Latin America Regional Medical Conference, Buenos Aires Argentina, November 11-12, 2004.
- “The Role of Atomoxetine in the Treatment of ADHD”, XXIVth Collegium Internationale Neuro-Psychopharmacologicum, Paris, France, June 19-25, 2004.

- "Overview of Nonstimulant Treatments for ADHD", Warren Wright Lecture, Northwestern University, Chicago, IL, April 23, 2004.
- "Update on ADHD." 7th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Chicago, IL, April 22-25, 2004.
- "Update on the Treatment of ADHD". Duke University Medical Center, Division of Child & Adolescent Psychiatry, Durham, NC, March 24th, 2004.
- "Update on ADHD: Is the Treatment of ADHD a 'Done Deal' or is There Still Need for Improvement?" AACAP 2004 Psychopharmacology Update Institute, New York, NY, January 16-17, 2004.
- "Presentation of the Treatment of a Child Using a New, Long-duration Medication". AACAP 2004 Psychopharmacology Update Institute, New York, NY, January 16-17, 2004.
- "New Pharmacological Treatments in ADHD", 1st International Congress in ADHD, Asociacion Mexicana por el deficit de atencion, hiperactividad y Trastornos asociados A.C., Mexico City, Mexico, November 15, 2003.
- "New and Emerging Pharmacotherapies in ADHD", Annual Meeting of the IG-ADHD, Koblenz, Germany, November 8, 2003.
- "Optimizing Symptom Relief in Patients with ADHD: Treatment and Effects". Symposium presented at the Annual meeting of the American Academy of Pediatrics, New Orleans, LA, November 4, 2003.
- "Treatment for Adolescents with Depression Study (TADS)". March JS, Emslie GJ, Curry JF, Kratochvil CK, Silva S. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.
- "Assessment of Safety in Child Mental Health Research: Obstacles and Opportunities", Symposium Rapporteur. Annual meeting of the American Academy of Child & Adolescent Psychiatry, Miami, FL, October 14-19, 2003.
- "Non-stimulant Treatment of ADHD", Columbia University and New York State Psychiatric Institute Grand Rounds, New York, NY, October 8, 2003.
- "New Directions in the Treatment of ADHD", Henry Ford Hospital Grand Rounds, Detroit, Michigan, September 25, 2003.
- "New ADHD Treatment Options", New York University Child Study Center Grand Rounds, New York, NY, September 19, 2003.
- "New Developments in the Pharmacotherapy of Children & Adolescent ADHD", at Wayne State University Symposium "New Advances in the Assessment and Treatment of ADHD Across the Lifespan", Detroit, MI, September 13, 2003.
- "Pharmacotherapy of Young Children and Adults with ADHD" at Wayne State University Symposium "New Advances in the Assessment and Treatment of ADHD Across the Lifespan", Detroit, MI, September 13, 2003.
- "New and Emerging Pharmacotherapies for ADHD", University of Texas Health Science Center at San Antonio, San Antonio, Texas, September 2, 2003.
- "New ADHD Treatment Options in Adults", University of Cincinnati Grand Rounds, Cincinnati, OH, May 14, 2003
- "New ADHD Treatment Options", Cincinnati Children's Hospital Grand Rounds, Cincinnati, OH, May 14, 2003

- "A Randomized, Placebo-Controlled Study of Once-Daily Atomoxetine in the School Setting in Children with ADHD", Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 20, 2003.
- "Treatment of ADHD with Nonstimulants", 1st Annual Child and Adolescent Psychiatry: The Place for Pharmacotherapy and Psychotherapy, Washington, DC, April 4-5, 2003.
- "New ADHD Treatment Options, 8th Annual Psychopharmacology Research Conference," Sponsored by the Nevada Psychiatric Association and American Psychiatric Association, Las Vegas, Nevada, February 13, 2003.
- "Pharmacotherapeutic Research in Pediatric ADHD," Children's Hospital of Michigan & Wayne State University Grand Rounds, Detroit, MI, February 11, 2002.
- "An Introduction to the Children's Regulations and IRB Issues Pertinent to Pediatric Research." Annual Meeting of Public Responsibility in Medicine and Research, San Diego, CA, November 18, 2002.
- "Update on Atomoxetine: A New Nonstimulant for ADHD." Annual Meeting of the American Association of Child & Adolescent Psychiatry, San Francisco, CA, October 25, 2002.
- "Can Newer Agents and Formulations Improve Outcomes in Patients with ADHD?" Annual Meeting of the American Association of Pediatrics, Boston, MA, October 21, 2002.
- "The Recognition and Treatment of Childhood Depression, at Depression: Management Across the Lifecycle, Sponsored by the Medical University of South Carolina, Charleston, SC, October 12, 2002."
- "New and Emerging Pharmacotherapies for ADHD, at Pharmacology of ADHD in the 21st Century: A Window into the Future", Sponsored by the National Association for Continuing Education, Toronto, Ontario, October, 4, 2002.
- "New ADHD Treatment Options on the Horizon." 155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18, 2002.
- "Principal Investigator's Challenge." AACAP Research Forum, 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI, October 25, 2001.
- "Atomoxetine: A new Non-Dopaminergic Intervention for ADHD." 48th Annual American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI, October 23-28, 2001.
- "Expanding Treatment Options for ADHD: New Alternatives." Annual Meeting of the American Academy of Pediatrics, San Francisco, CA, October 21, 2001.
- "Treatment Research in Child and Adolescents from Design to Implementation of Clinical Trials Workshop: Successful Recruitment Strategies in Multi-Site Trials." 41st Annual NCDEU Meeting, Phoenix, AZ, May 28, 2001.
- "Challenges and Opportunities in Recruiting Participants for NIMH Multi-Center Clinical Trials: Current Experiences for the Field Studies in Children." 41st Annual NCDEU Meeting, Phoenix, AZ, May 28, 2001.
- "Evidence for genetic determinants of ADHD." Scientific Proceedings of the 56th Annual Society of Biological Psychiatry Meeting, New Orleans, LA, May 3, 2001.

"Human research issues involving people with mental illness, dementia, or cognitive impairment." 11th World Congress of the International Association for the Scientific Study of Intellectual Disabilities, Seattle WA, August 1, 2000.

"Psychiatry Residents as Active Researchers: The Experiences of Two Programs" American Association of Directors of Psychiatry Residency Training, Charleston, SC, 1997

Regional Symposia Chaired

"Child and Adolescent Mental Health Conference", sponsored by UNMC Department of Psychiatry, Omaha, NE, September 23, 2005

"ADHD across the Ages: Preschool to Adulthood", conference sponsored by UNMC Department of Psychiatry, Omaha, NE, September 26, 2003.

Regional Presentations

"Child & Adolescent Mental Health Issues", 38th Family Medicine Review Course, UNMC, Omaha, NE, April 2009

"Depression in Children and Adolescents: Relevance of Recent Research to Clinical Practice", Children's Hospital, Omaha, Nebraska, September 2008

"Update on ADHD", University of South Dakota, Sioux Falls, SD, April 18, 2008

"Update on ADHD Pharmacotherapy", Nebraska Pharmacists Association Annual Convention, Lincoln, NE, July 20, 2007

"Treatment for Adolescent Depression: FDA Hearings, Research Findings and Clinical Implications", Children's Hospital, Omaha, NE, February 3, 2006

"Attention Deficit Hyperactivity Disorder", Child & Adolescent Mental Health Conference sponsored by UNMC Department of Psychiatry, Omaha, NE September 23, 2005

"Child and Adolescent Depression", UNMC Department of Family Practice Grand Rounds, Omaha, NE; May 11, 2005

"Pediatric Depression", 8th Annual Practical Pediatrics: 2005 Update, Omaha, NE, February 18, 2005

"Pediatric Depression: Clinical Issues, Controversies and Current Research", UNMC Department of Psychiatry Grand Rounds, Omaha, NE; January 27, 2005

"Update on Pediatric Depression", Nebraska Psychological Association 2004 Fall Conference; Omaha, NE, October 1, 2004.

"Current Perspectives in Pediatric Psychopharmacology", 10th Annual Midwest Neuropsychopharmacology Update; Kansas City, MO, September 10, 2004.

"Update on New and Emerging Pharmacotherapies for ADHD", Annual Meeting of the Nebraska Pharmacists Association, Kearney, NE, July 30, 2004.

"Attention-Deficit/Hyperactivity Disorder", 7th Annual Practical Pediatrics: 2004 Update; Omaha, NE, February 20, 2004.

"Biological Aspects of ADHD", Grand Rounds, Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE, January 28, 2004.

- “Pharmacotherapy for ADHD”, ADHD across the Ages: Preschool to Adulthood Symposium, Conference sponsored by UNMC Department of Psychiatry, Omaha, NE, September 26, 2003.
- “Biological Aspects of ADHD”, John A. Wiebe, Jr. Research Lecture Series, Children’s Hospital, Omaha, NE, September 12, 2003
- “New Treatments for ADHD”, Nebraska Chapter of the American Academy of Pediatrics, Children’s Hospital, Omaha, NE, April 11, 2003
- “ADHD in Children and Adolescents”, Mary Lanning Department of Pediatrics Grand Rounds; Hastings, NE, September 28, 2002
- “Attention Deficit Hyperactivity Disorder and Depression”, UNMC Symposium on Treating Depression in the Complex Patient, Omaha, NE, April 5, 2002
- “ADHD Diagnosis and Treatment in Children, Adolescents and Adults”; University of Nebraska Medical Center, Department of Psychiatry, Grand Rounds, Omaha, NE, November 7, 2001.
- “Child and Adolescent Depression”, Practical Pediatrics, 2001, Creighton University and Children’s Hospital, Omaha, NE, February 16, 2001.
- “Treatment of ADHD: An Overview”, UNMC Department of Pharmacology, Omaha, NE, November 17, 2000
- “ADHD Linking Basic Science and Clinical Research”; Cell Biology and Anatomy Seminar Series; UNMC, Omaha, NE, August 29, 2000
- “ADHD in Children & Adolescents”, Richard Young Center Family Practitioner Psychiatric Update, Omaha, NE, July 28, 2000.
- “Major Depression in Children and Adolescents”, Mary Lanning Department of Pediatrics Grand Rounds; Hastings, NE, April, 2000
- “Attention Deficit Hyperactivity Disorder”, Children’s Hospital Grand Rounds; Omaha, NE, March 24, 2000
- “Treatment of Adolescent Depression Study”, Nebraska Department of Psychiatry Grand Rounds; Omaha, NE, March 8, 2000
- “Attention Deficit Hyperactivity Disorder Practical Pediatrics: 2000 Update”, Creighton University and Children’s Hospital, Omaha, NE, February 18, 2000
- “OCD in Children and Adolescents”, Creighton-Nebraska Department of Psychiatry Grand Rounds, Omaha, NE 1999
- “Risk Taking Behaviors of Youth” Symposium Entitled “Gangs, Drugs & Violence” Saint Joseph Hospital, Omaha, NE 1998
- “Psychopharmacology of Child and Adolescent Anxiety Disorders”, Creighton-Nebraska Department of Psychiatry Grand Rounds, Omaha, NE 1998
- “Pediatric Psychopharmacology” Monthly Seminar, Boys Town National Research Institute Omaha, NE 1997 to 1998
- “Psychopharmacology in School-aged Children”, Fayetteville Area Health Education Center Workshop, Fayetteville, NC 1997
- “Externalizing Disorders” Children’s Psychiatric Institute Conference, Chapel Hill, NC, 1996

Lectures In Team-Taught Courses
Medical Students

University of Nebraska Medical Center, Psychiatry Clerkship. 8 lectures annually, 2005-2007

M2 Core Curriculum, University of Nebraska Medical School, Omaha, NE, 2 lectures annually, 2000- Present

Creighton University School of Medicine, Pediatrics Clerkship, 8 lectures annually, 1998- 2004

Residents

- Psychiatry Residents, UNMC/Creighton: 4 lectures annually
- Child Psychiatry Residents, UNMC/Creighton: 16 lectures annually

UNMC Fellows

Introduction to the Institutional Review Board, Clinical Research Symposium, University of Nebraska Medical Center, Omaha, NE, annually 2001- 2010

Allied Health Students, UNMC

Introduction to the Institutional Review Board and Human Subjects Protections, University of Nebraska Medical Center, Omaha, NE, annually 2001- 2009

Courses Coordinated

Pediatric Psychopharmacology, Child & Adolescent Psychiatry Residents, Creighton-Nebraska Joint Residency Program, 2000- 2010

Psychopharmacology Update Child & Adolescent Psychiatry Residents, Creighton-Nebraska Joint Residency Program, 2000- 2010

Cognitive Behavioral Therapy Child & Adolescent Psychiatry Residents, Creighton-Nebraska Joint Residency Program, 2000- 2001

Graduate Students

Supervisory Committee for Ph.D. Candidate (b) (6) 2011-Present
Supervisory Committee for Ph.D. Candidate (b) (6), 2001-2003

Mentorship

(b) (6)